TTHX1114(NM141) in Combination With DWEK/DSO

Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04676737

Enrollment

Registered

2020-12-21

Start date

2021-02-01

Completion date

2023-01-13

Last updated

2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs

Brief summary

Open label, single-treatment, with a concurrent non-treatment control

Interventions

DRUGTTHX1114(NM141)

TTHX1114

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months * Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm * Subjects in Group 2 must have a stable Fellow Eye with adequate function Key

Exclusion criteria

* Secondary corneal/ocular pathology in the Study Eye * Prior refractive surgery in the Study Eye * Prior exposure to TTHX1114

Design outcomes

Primary

Measure	Time frame	Description
Best Corrected Visual Acuity	Day 28	Change from baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026